Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
Metastasis02:30

Metastasis

5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.

Frontiers in endocrinology·2026
Same author

Acinar cell plasticity and subtype specification during acinar-to-ductal metaplasia and pancreatic cancer progression.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis.

Cancer letters·2026
Same author

Endocytic patch dynamics are differentially regulated at distinct cell sites in fission yeast.

Journal of cell science·2025
Same author

Unraveling the role of mucins and gut microbiota in gastrointestinal cancers chemoresistance.

Biochimica et biophysica acta. Reviews on cancer·2025
Same author

Ribosome biogenesis, altered metabolism and ribotoxic stress response in pancreatic ductal adenocarcinoma tumor microenvironment.

Cancer letters·2025

Related Experiment Video

Updated: Sep 19, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

534

Deciphering ETS2: An indispensable conduit to cancer.

Samu John1, Dhanya Kalathil2, Ramesh Pothuraju3

  • 1Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India; Research Centre, University of Kerala, Thiruvananthapuram 695034, India; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.

Biochimica Et Biophysica Acta. Reviews on Cancer
|June 9, 2025
PubMed
Summary

E26 Transformation-Specific homolog 2 (ETS2) acts as a double-edged sword in cancer, exhibiting both tumor-suppressive and oncogenic roles. Understanding ETS2

Keywords:
Cancer therapyDisease and infectionETS2GOF mtp53Hallmarks of cancerRegulatory mechanismStructure and function

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K
Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

534
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K
Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.0K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • E26 Transformation-Specific homolog 2 (ETS2) is a key transcription factor involved in cellular development and survival.
  • ETS2 primarily functions by regulating target gene promoters but also utilizes other mechanisms.
  • Its role in cancer is complex, acting as both a tumor suppressor and an oncogene depending on the context.

Purpose of the Study:

  • To provide a comprehensive review of ETS2's role in health and disease, with a focus on cancer.
  • To explore the signaling pathways, post-translational modifications, miRNA regulations, and protein-protein interactions involving ETS2.
  • To highlight ETS2's potential as a biomarker and therapeutic target in oncology.

Main Methods:

  • Literature review and synthesis of existing research on ETS2.
  • Analysis of ETS2's involvement in the 'hallmarks of cancer'.
  • Discussion of regulatory mechanisms including signaling pathways, PTMs, miRNA, and PPIs.

Main Results:

  • ETS2 exhibits context-specific dual roles (tumor suppressive or oncogenic) in various cancers.
  • ETS2 is implicated in multiple 'hallmarks of cancer', influencing tumor development and progression.
  • Various regulatory mechanisms (signaling, PTMs, miRNA, PPIs) modulate ETS2 function.

Conclusions:

  • ETS2 is a complex factor with significant implications in cancer, acting as a potential biomarker.
  • Elucidating ETS2's precise mechanisms in different cancer contexts is crucial for therapeutic development.
  • Further research into ETS2 could lead to novel clinical strategies and outcomes.